Replicating recombinant adenovirus vectors, compositions, and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9750801-B2
Application number	US-201514632433-A
Country	US
Kind code	B2
Filing date	Feb 26, 2015
Priority date	Feb 28, 2014
Publication date	Sep 5, 2017
Grant date	Sep 5, 2017

Abstract

Replicating recombinant adenovirus vectors derived from human adenovirus serotype 26 or human adenovirus serotype 35 are described. The replicating recombinant adenovirus vectors have attenuated replicative capacity as compared to that of the corresponding wild-type adenovirus. They can be used for stable expression of heterologous genes in vivo. Also described are compositions and methods of using these recombinant adenovirus vectors to induce an immune response in a subject, and vaccinate a subject against an immunogenic human immunodeficiency virus (HIV) infection.

First claim

We claim:

1. A replicating recombinant adenovirus vector, comprising a recombinant human adenovirus serotype 26 genome having:
(a) a promoter operably linked to a heterologous nucleic acid sequence;
(b) a functional E1 coding region that is sufficient for viral replication;
(c) a deletion in the E3 coding region; and
(d) a deletion in the E4 coding region, provided that E4 open reading frame 6/7 is not deleted.

2. The replicating recombinant adenovirus vector of claim 1 ,
wherein the heterologous nucleic acid sequence is located between left inverted terminal repeat (ITR) and 5′-end of the functional E1 coding region.

3. The replicating recombinant adenovirus vector of claim 1 , wherein the heterologous nucleic acid sequence encodes an immunogenic polypeptide.

4. The replicating recombinant adenovirus vector of claim 1 , wherein the heterologous nucleic acid sequence encodes an HIV antigen.

5. The replicating recombinant adenovirus vector of claim 1 , wherein the heterologous nucleic acid sequence encodes a mosaic HIV antigen.

6. The replicating recombinant adenovirus vector of claim 1 , wherein the heterologous nucleic acid sequence encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 48 or SEQ ID NO: 50.

7. The replicating recombinant adenovirus vector of claim 1 , wherein the vector is lyophilized.

8. A replicating recombinant adenovirus vector comprising a recombinant human adenovirus serotype 26 genome having:
(a) a promoter operably linked to a heterologous nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 48 or SEQ ID NO: 50;
(b) a functional E1 coding region that is sufficient for viral replication encoding the amino acid sequences of SEQ ID NOs: 14-16;
(c) a partially deleted E3 coding region consisting of the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 6; and
(d) a partially deleted E4 coding region consisting of the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 22.

9. The replicating recombinant adenovirus vector of claim 8 , wherein the heterologous nucleic acid sequence is located between left ITR and 5′-end of the functional E1 coding region.

10. The replicating recombinant adenovirus vector of claim 9 , wherein,
(a) the promoter is CMV promoter having the nucleotide sequence of SEQ ID NO: 51, and the heterologous nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO: 47 or SEQ ID NO: 49;
(b) the functional E1 coding region comprises the nucleotide sequence of SEQ ID NO: 13;
(c) the partially deleted E3 coding region consists of the nucleotide sequence of SEQ ID NO: 5; and
(d) the partially deleted E4 coding region consists of the nucleotide sequence of SEQ ID NO: 23.

11. A composition comprising the replicating recombinant adenovirus vector of claim 1 and a pharmaceutically acceptable carrier.

12. The composition of claim 11 , being formulated for oral administration to a subject.

13. The composition of claim 12 , being an enteric-coated capsule.

14. A method of producing a replicating adenovirus particle, comprising:
introducing the replicating recombinant adenovirus vector of claim 1 into a cell under conditions sufficient for replication of the recombinant adenovirus genome and packaging of the adenovirus particle in the cell; and
collecting the adenovirus particle.

15. A method of producing an immune response in a subject, comprising: administering to the subject an immunogenically effective amount of the composition according to claim 11 .

16. The method of claim 15 , wherein the composition is orally administered to the subject.

17. A method of producing an immune response in a human subject against an HIV infection, comprising: orally administering to the subject an immunogenically effective amount of a composition comprising a pharmaceutically acceptable carrier and a replicating recombinant adenovirus vector comprising a recombinant human adenovirus serotype 26 genome having:
(a) a promoter operably linked to a heterologous nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 48 or SEQ ID NO: 50;
(b) a functional E1 coding region that is sufficient for viral replication encoding the amino acid sequences of SEQ ID NOs: 14-16;
(c) a partially deleted E3 coding region consisting of the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 6; and
(d) a partially deleted E4 coding region consisting of the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 22,
wherein the heterologous nucleic acid sequence is located between left ITR and 5′-end of the functional E1 coding region.

18. The method of claim 17 , wherein
(a) the promoter is CMV promoter having the nucleotide sequence of SEQ ID NO: 51 and the heterologous nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO: 47 or SEQ ID NO: 49;
(b) the functional E1 coding region comprises the nucleotide sequence of SEQ ID NO: 13;
(c) the partially deleted E3 coding region consists of the nucleotide sequence of SEQ ID NO: 5; and
(d) the partially deleted E4 coding region consists of the nucleotide sequence of SEQ ID NO: 23.

19. The replicating recombinant adenovirus vector of claim 1 , comprising a partially deleted E3 coding region, wherein all nucleic acid sequence of the E3 coding region with the exception of nucleic acid sequence encoding the E3 12.5K protein product is deleted.

20. The replicating recombinant adenovirus of claim 19 , wherein a replicative capacity of the vector is attenuated by at least about 80-fold, as compared to a replicative capacity of a wild-type human adenovirus serotype 26, and the attenuation is measured in vitro in non-complementing human A549 cells or human HuTu80 cells.

Assignees

• Beth Israel Deaconess Medical Ct Inc
• Crucell Holland Bv
• Janssen Vaccines & Prevention Bv

Inventors

• Barouch Dan
• Abbink Peter

Classifications

• C12N2710/16143

  viral genome or elements thereof as genetic vector · CPC title

• A61K39/21 Primary

  Retroviridae, e.g. equine infectious anemia virus · CPC title

• C12N2710/10343

  viral genome or elements thereof as genetic vector · CPC title

• C12N2740/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N15/86

  Viral vectors · CPC title